Skip to main
OVID

Ovid Therapeutics (OVID) Stock Forecast & Price Target

Ovid Therapeutics (OVID) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ovid Therapeutics is a promising biopharmaceutical company with potential first-in-class and best-in-class drugs in its pipeline, targeting severe epileptic neurological disorders with multi-billion dollar market opportunities. The recent KCC2 R&D event showcased additional preclinical data and a detailed clinical roadmap for OV4071 and OV329, while the company's balance sheet strength and cash runway provide a solid foundation for future development. With multiple upcoming readouts and potential for expanded indications, Ovid remains a top pick with potential upside to current projections.

Bears say

Ovid Therapeutics is dedicated to developing novel therapeutics for epilepsy disorders, with their most advanced program being OV329, which is advancing to Phase 2 studies. With revenue potential projected at over $6B, Ovid is exploring multiple potential therapeutic applications for OV4071, including schizophrenia and psychoses, and is advancing next-generation KCC2 activators from its proprietary library of compounds. However, without clinical data to support its effectiveness and concerns about potential prolonged drug effects, there is high risk and potential for setbacks, leading to a negative outlook for the stock.

Ovid Therapeutics (OVID) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ovid Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ovid Therapeutics (OVID) Forecast

Analysts have given Ovid Therapeutics (OVID) a Buy based on their latest research and market trends.

According to 7 analysts, Ovid Therapeutics (OVID) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ovid Therapeutics (OVID)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.